logo
1 Safe-and-Steady Stock to Own for Decades and 2 to Steer Clear Of

1 Safe-and-Steady Stock to Own for Decades and 2 to Steer Clear Of

Yahoo22-04-2025
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Choosing the wrong investments can cause you to fall behind, which is why we started StockStory - to separate the winners from the losers. That said, here is one low-volatility stock providing safe-and-steady growth and two that may not keep up.
Rolling One-Year Beta: 0.22
Founded by Dave Thomas in 1969, Wendy's (NASDAQ:WEN) is a renowned fast-food chain known for its fresh, never-frozen beef burgers, flavorful menu options, and commitment to quality.
Why Is WEN Not Exciting?
5.6% annual revenue growth over the last five years was slower than its restaurant peers
Demand is forecasted to shrink as its estimated sales for the next 12 months are flat
High net-debt-to-EBITDA ratio of 7× increases the risk of forced asset sales or dilutive financing if operational performance weakens
At $12.70 per share, Wendy's trades at 12.3x forward price-to-earnings. To fully understand why you should be careful with WEN, check out our full research report (it's free).
Rolling One-Year Beta: 0.74
With roots dating back to 1807 when Charles Wiley opened a small printing shop in Manhattan, John Wiley & Sons (NYSE:WLY) is a global academic publisher that provides scientific journals, books, digital courseware, and knowledge solutions for researchers, students, and professionals.
Why Should You Sell WLY?
Annual sales declines of 1.6% for the past five years show its products and services struggled to connect with the market during this cycle
Flat earnings per share over the last two years underperformed the sector average
Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 4.3 percentage points
Wiley is trading at $41.65 per share, or 17.4x forward EV-to-EBITDA. Check out our free in-depth research report to learn more about why WLY doesn't pass our bar.
Rolling One-Year Beta: 0.86
Spun out of Post Holdings in 2019, Bellring Brands (NYSE:BRBR) offers protein shakes, nutrition bars, and other products under the PowerBar, Premier Protein, and Dymatize brands.
Why Will BRBR Beat the Market?
Products are selling at a rapid clip as its unit sales averaged an outstanding 21.2% growth rate over the past two years
Earnings per share grew by 30.9% annually over the last three years, massively outpacing its peers
Stellar returns on capital showcase management's ability to surface highly profitable business ventures
BellRing Brands's stock price of $73.21 implies a valuation ratio of 32.2x forward price-to-earnings. Is now the time to initiate a position? Find out in our full research report, it's free.
The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.
While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years.
Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Axon (+711% five-year return). Find your next big winner with StockStory today for free.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Johnson & Johnson (JNJ): I Would 'Love' If Trump Praised The Company, Says Jim Cramer
Johnson & Johnson (JNJ): I Would 'Love' If Trump Praised The Company, Says Jim Cramer

Yahoo

timean hour ago

  • Yahoo

Johnson & Johnson (JNJ): I Would 'Love' If Trump Praised The Company, Says Jim Cramer

We recently published . Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently discussed. Johnson & Johnson (NYSE:JNJ) is one of the largest and most well-known pharmaceutical companies in the world. Its shares have gained a modest 8.9% year-to-date as the firm has struggled from headwinds such as a judge rejecting its $10 billion talc powder cancer lawsuit settlement. In his previous comments about Johnson & Johnson (NYSE:JNJ), Cramer has called the firm one of the 'best-run companies in America' and praised its balance sheet and drug pipeline. This time around, he discussed the upcoming earnings report and an analyst note: '[On a Mizuho note saying POTUS would praise LLY and JNJ] I would love that, that won't happen. You know why it won't happen? See there's someone in the health and human services department that's not crazy about, about big pharma and the way we think about it. 'JNJ, JNJ I don't know. JNJ's going to report this week they've got a talc problem still but I thought the President was going to act against the plaintiffs, probably has.' A smiling baby with an array of baby care products in the foreground. As for Johnson & Johnson (NYSE:JNJ) 's balance sheet and pipeline, here's what Cramer said: 'Or let's consider Johnson & Johnson, triple A balance sheet, many drugs in the pipeline, one of the best-run companies in America, if not the world, with perhaps the most billion-dollar franchises of any pharmaceutical company I know, but JNJ only yields 3.55%, and it's got this terrible legal overhang related to allegations that its talcum powder, no longer in the market, caused ovarian cancer. We don't know how open-ended the claims are. Can you tolerate that risk? I'd love to say just go buy JNJ, but where? What price? That yield is no longer enough to compensate you for the risk, especially if you don't know if RFK Jr dislikes some of their drug delivery mechanisms and formulas, so people are staying away from that, too, not just because of the bonds. JNJ… 3.3%.' While we acknowledge the potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.

LASE Investors Have Opportunity to Join Laser Photonics Corporation Fraud Investigation with the Schall Law Firm
LASE Investors Have Opportunity to Join Laser Photonics Corporation Fraud Investigation with the Schall Law Firm

Associated Press

time3 hours ago

  • Associated Press

LASE Investors Have Opportunity to Join Laser Photonics Corporation Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)--Jul 13, 2025-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Laser Photonics Corporation ('Laser Photonics' or 'the Company') (NASDAQ: LASE ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Laser Photonics disclosed in a May 29, 2025, SEC filing that it had 'received a notice from Nasdaq Listing Qualifications department of the Nasdaq Stock Market LLC ('Nasdaq') stating that since it had not received the Company's Form 10-Q for the period ended March 31, 2025, and because the Company remains delinquent in filing its Form 10-K for the period ended December 31, 2024 (the 'Initial Delinquent Filing'), the Company does not comply with Nasdaq's Listing Rules for continued listing.' The filing continued, 'the Company has until June 16, 2025, to submit a plan to regain compliance with respect to these delinquent reports.' Based on this news, shares of Laser Photonics fell by more than 6.5% on the next day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at [email protected]. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. View source version on CONTACT: The Schall Law Firm Brian Schall, Esq. 310-301-3335 [email protected] KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL SOURCE: The Schall Law Firm Copyright Business Wire 2025. PUB: 07/13/2025 03:36 PM/DISC: 07/13/2025 03:36 PM

Thermo Fisher (TMO) Gets a Buy from Wells Fargo
Thermo Fisher (TMO) Gets a Buy from Wells Fargo

Business Insider

time3 hours ago

  • Business Insider

Thermo Fisher (TMO) Gets a Buy from Wells Fargo

In a report released on July 11, Brandon Couillard from Wells Fargo maintained a Buy rating on Thermo Fisher, with a price target of $570.00. The company's shares closed last Friday at $434.86. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Couillard covers the Healthcare sector, focusing on stocks such as Exact Sciences, Thermo Fisher, and Maravai Lifesciences Holdings. According to TipRanks, Couillard has an average return of 14.9% and a 60.65% success rate on recommended stocks. In addition to Wells Fargo, Thermo Fisher also received a Buy from Evercore ISI's Vijay Kumar in a report issued on July 8. However, on July 11, Scotiabank downgraded Thermo Fisher (NYSE: TMO) to a Hold. The company has a one-year high of $627.88 and a one-year low of $385.46. Currently, Thermo Fisher has an average volume of 2.74M.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store